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for unresectable or metastatic melanoma
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Abstract 
Background: For unresectable or metastatic melanoma, first-line ipilimumab has demonstrated long-term survival 
benefits over a 7-year period. First-line treatment with BRAF inhibitors has demonstrated efficacy in clinical trials 
with up to 3 years of follow-up. The long-term comparative efficacy and costs of ipilimumab and BRAF inhibitors are 
unknown.
Methods: Patient-level data from 12 clinical studies for ipilimumab were used. Survival data were extracted from 
included clinical trials for BRAF inhibitors based on a systematic literature review. Different parametric survival models, 
including exponential, Gompertz, log-normal, and Weibull models, were used to fit reported overall survival (OS) data 
and to project long-term survival for BRAF inhibitors. Survival benefits were measured in terms of total life-months 
gained as calculated by the area under the curve of OS Kaplan–Meier curves for the observed ipilimumab data and 
projected BRAF inhibitor data. Total life-months gained and cumulative costs per life-month gained were compared 
between ipilimumab and BRAF inhibitors.
Results: The systematic literature review identified six randomized-controlled trials of BRAF inhibitors for subse-
quent analyses. With 7-year follow-up, ipilimumab was associated with a total of 28.5 life-months gained. Based on 
the Weibull model, the extrapolated total life-months gained for BRAF inhibitors were 26.5 months for dabrafenib, 
21.3 months for trametinib, 14.3 months for vemurafenib, and 24.6 months for dabrafenib + trametinib. In sensi-
tivity analyses, extrapolated total life-months gained varied across the three other models, ranging from 13.7 to 
36.8 months across therapies. Cumulative costs per life-month gained with ipilimumab decreased steadily over time, 
while the costs remained constant for BRAF inhibitors due to continuous dosing. By year 3, cumulative costs per 
life-month gained were the lowest with ipilimumab; by year 7, the costs were $4281 for ipilimumab, compared with 
$8920 for dabrafenib, $10,211 for trametinib, $11,002 for vemurafenib, and $19,132 for the dabrafenib + trametinib 
combination therapy.
Conclusions: Ipilimumab was associated with a better long-term cost-per-life month compared to BRAF agents. 
Long-term extrapolation of survival with BRAF agents was uncertain, and showed no evidence of prolonged survival 
compared to ipilimumab.
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Background
Melanoma is one of the most deadly cancers, contribut-
ing to 80 % of skin cancer-related deaths [1]. It has been 
estimated that nearly 10,000 patients in the United States 
will die from melanoma in 2015 [2]. In 4 % of initial diag-
noses, the cancer has already metastasized to other sites 
in the body [2]; in up to 40 % of early-stage melanoma, 
there will be disease recurrence, usually with lymph node 
invasion [3, 4]. Unresectable or metastatic melanoma is 
difficult to control because it is highly heterogeneous at 
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the molecular level and continues to progress throughout 
its clinical course [5].
Treatment choices for unresectable or metastatic mel-
anoma have rapidly evolved in the last decade due to a 
better understanding of cancer mechanisms [6]. Ipili-
mumab, dabrafenib, trametinib, vemurafenib, or dab-
rafenib +  trametinib combination therapy are approved 
by the US Food and Drug Administration (FDA) as 
first-line treatments [7]. The immuno-oncology agent 
ipilimumab induces a strong anti-cancer immune 
response through a sustained but non-specific mecha-
nism of activation of T cells [8–10]. In contrast, the 
targeted therapies dabrafenib, trametinib, and vemu-
rafenib are directed against a specific tumor cell sur-
vival pathway, the mitogen activated protein kinase/
extracellular signal-regulated kinase (MEK) pathway 
[11]. About 60 % of melanocytes include the mutation of 
a single amino acid (V600E or K) to constitutively acti-
vate the BRAF kinase, a key player in the MEK pathway 
[11]. Vemurafenib and dabrafenib selectively inhibit this 
active mutant kinase [11]; trametinib provides addi-
tional inhibition of the downstream MEK pathway. All 
three agents are approved for use in patients with BRAF 
V600E or V600K mutations; the combined treatment of 
dabrafenib  +  trametinib is associated with significantly 
better efficacy relative to BRAF monotherapies (e.g., dab-
rafenib or vemurafenib) [12–15].
Given that metastatic melanoma progresses rapidly [16, 
17] and evolves unpredictably due to molecular heteroge-
neity [5], optimal treatment selection is crucial. Despite a 
wide range of available treatments, each therapy is asso-
ciated with a distinct set of benefits and risks. Ipilimumab 
only requires a short period of treatment (four infusions 
over 3 months) to achieve clinical response, which can be 
long-lasting. In a pooled analysis of 12 clinical studies, 
first-line ipilimumab demonstrates long-term survival 
benefits over a 7-year period with survival rates pla-
teauing and staying constant at ~21 % after 3 years [18]. 
However, the disadvantages of ipilimumab are that the 
treatment effect can be delayed by  ~3  months [19] and 
initial response rates are low [19–24]. In contrast, BRAF 
inhibitors present the advantage of high initial response 
rates [12, 25–29]. However, response to BRAF inhibitors 
can be temporary, as resistance usually develops within 
6 months of treatment initiation [30], and their long-term 
efficacy remains unclear. A recent study among patients 
treated with vemurafenib shows that 3- and 4-year sur-
vival rates are 26 and 19 %, respectively [31]. However, for 
other BRAF treatments, maximum follow-up periods in 
clinical trials are only about 2–3 years. In addition, for a 
large proportion of patients with melanoma—those who 
have wild-type BRAF—treatment with BRAF inhibitors 
is not approved by the FDA due to the possibility of dis-
ease exacerbation [32].
The high costs of cancer medicines are increasingly 
drawing public attention. Costs, together with clini-
cal benefit (i.e., efficacy) and toxicity, are included in 
the American Society of Clinical Oncology (ASCO) 
conceptual framework to assess the value of cancer 
treatments [33]. To date, the long-term comparative 
value, including efficacy and costs, of first-line treat-
ments with ipilimumab and BRAF inhibitors remains 
unknown. The current study aimed to address this 
knowledge gap by comparing long-term survival and 
costs of ipilimumab, dabrafenib, trametinib, vemu-
rafenib, and dabrafenib + trametinib combination ther-
apy. A systematic literature review was conducted to 
identify randomized controlled trials (RCTs) of BRAF 
inhibitors as first-line treatments for unresectable or 
metastatic melanoma. Based on the reported overall 
survival results of these treatments, parametric sur-
vival models were used to project long-term survival 
benefits, measured in total life-months gained. Further-
more, in order to fairly represent long-term drug costs 
for ipilimumab with limited doses versus BRAF inhibi-
tors with a continuous dosing schedule, the cumulative 
drug costs per life-month gained were calculated and 
compared descriptively.
Results
Systematic literature review
A total of 654 studies were initially identified from data-
base searches and supplemental manual searches of 
recent ASCO and European Society for Medical Oncol-
ogy (ESMO) conference abstracts (Fig.  1). After 2 lev-
els of screening, 30 publications were then evaluated in 
detail for their eligibility for the study’s analysis; among 
these, seven were excluded because they were not RCTs, 
nine were excluded because they reported second-line 
or mixed first- and second-line treatments (except for 
trametinib, of which the only available RCT METRIC 
trial [34] included mixed first- and second-line patients), 
seven were excluded because they were publications of 
the same trial, and only the latest results were included 
for subsequent analysis.
A total of six RCTs investigating BRAF inhibitors for 
previously untreated metastatic melanoma reported 
overall survival results and were included in this study: 
dabrafenib was investigated in trials BREAK-3 [35, 36] 
and COMBI-d [13, 37]; trametinib was investigated in 
trial METRIC [34]; vemurafenib was investigated in tri-
als BRIM3 [26, 28], COMBI-v [12], and co-BRIM [38]; 
and dabrafenib  +  trametinib was investigated in tri-
als COMBI-d [13, 37] and COMBI-v [12]. Among 
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BRAF inhibitors, median overall survival ranged from 
9.2  months (for vemurafenib) [28] to 18.3  months (for 
dabrafenib +  trametinib) [12]. Median follow-up length 
ranged from 3.8  months (for vemurafenib) [28] to 
24 months (for dabrafenib + trametinib) [37].
Parametric survival modeling for overall survival 
following first‑line BRAF inhibitors
Four parametric survival models (Weibull, exponential, 
Gompertz, and log-normal) were used to fit the reported 
overall survival results of BRAF inhibitors. The Akaike 
information criterion (AIC) value, an indicator of a mod-
el’s goodness-of-fit, did not differ substantially across the 
four models for each BRAF inhibitor (Additional file  1: 
Table S1). There was no specific model that had the best 
fit for all BRAF inhibitors. The Weibull model had been 
previously used to analyze overall survival of patients 
with metastatic melanoma [39, 40], so it was chosen as 
the base-case model. The other three models were used 
as sensitivity analyses.
Total life‑months gained
Survival benefits were measured by the area under the 
curve of the overall survival Kaplan–Meier curves as total 
life-months gained for the observed ipilimumab data and 
the projected BRAF inhibitor data. The Kaplan–Meier 
curve of observed long-term overall survival following 
first-line ipilimumab based on patient-level data from 
a pooled analysis of 12 clinical studies [18] is shown in 
Fig. 2. With 7-year follow-up, ipilimumab was associated 
Duplicate removed
• Duplicates (N = 136)
Eligible RCTs for data extraction
N = 7
Ti
tle
/A
bs
tra
ct
 S
cr
ee
ni
ng
Fu
ll 
Te
xt
 S
cr
ee
ni
ng
In
cl
ud
ed
Id
en
tif
ic
at
io
n
Records excluded (Level I) for the following reasons
(N = 570)
• Study population (N = 81)
• Intervention (N = 92)
• Study design or publication type (N = 288)
• Outcomes (N = 62)
• Minimum no. of patients (N = 47)
Records excluded (Level II) for the following reasons
(N = 54)
• Study population (N = 1)
• Intervention (N = 27)
• Study design or publication type (N = 9)
• Outcomes (N = 14)
• Minimum no. of patients (N = 3)
Records excluded (N = 16)
• Study population (N = 9)
• Non-RCTs (N = 7)
Eligible records for detailed review
N = 30
Among 30 eligible studies: (16 articles, 14 conference abstracts; 
23 RCTs, 7 Non-RCTs)
Eligible records for full text screening
N = 84
 (50 articles, 34 conference abstracts)
Eligible records for title/abstract screening
N = 654
 (506 articles, 148 conference abstracts)
Articles identified through 
database searches
N = 642
(370 from Embase and 
Medline, 190 from Medline in 
process, 82 from Cochrane)
Conference abstracts through 
database and supplemental 
manual searches
N = 148
 (ASCO: 85, ESMO: 63)
Fig. 1 PRISMA diagram for systematic literature review
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with a total of 28.5 life-months gained per patient. For 
BRAF inhibitors, which have relatively short follow-up, 
the total observed life-months gained per patient ranged 
from 7.3  months (for trametinib) to 21.5  months (for 
dabrafenib) (Table 1).
The Kaplan–Meier curves of observed and projected 
long-term overall survival following first-line treatment 
with BRAF inhibitors are shown in Fig.  3 for the base-
case Weibull model. With projected 7-year follow-up, 
the extrapolated total life-months gained per patient 
for BRAF inhibitors were 26.5  months for dabrafenib, 
21.3  months for trametinib, 14.3  months for vemu-
rafenib, and 24.6  months for dabrafenib  +  trametinib, 
based on the Weibull model (Table  1). In sensitivity 
analyses, extrapolated total life-months varied across 
three other models, ranging from a low of 13.7  months 
(for vemurafenib) to a high of 36.8  months (for dab-
rafenib + trametinib) across therapies (Table 1).
Cumulative costs per life‑month gained
The cumulative costs per life-month gained with BRAF 
inhibitors remained constant over time, as patients are 
dosed chronically with these treatments. In contrast, 
ipilimumab is administered with fixed doses, four infu-
sions over 3 months. Therefore the cumulative costs per 
life-month gained with ipilimumab decreased steadily 
over time (Fig.  4). By year 3, the cumulative costs per 
life-month gained were lower for ipilimumab relative to 
all BRAF inhibitors. By year 7, cumulative costs per life-
month gained were $4281 for ipilimumab, $8920 for dab-
rafenib, $10,211 for trametinib, $11,002 for vemurafenib, 
and $19,132 for dabrafenib + trametinib.
Discussion
Among the approved first-line treatments for unresect-
able or metastatic melanoma, there has not been any 
head-to-head RCT comparing ipilimumab, dabrafenib, 
trametinib, vemurafenib, and dabrafenib  +  trametinib. 
Ipilimumab is associated with an established long-term 
survival benefit [18], whereas BRAF inhibitors are asso-
ciated with high initial response [12–14, 25–29, 41, 42], 
but with limited long-term data. To provide additional 
evidence on the comparative value between ipilimumab 
and BRAF inhibitors, this study was undertaken to assess 
the long-term survival benefit and costs of these agents.
For the current study, parametric survival models were 
used to project long-term overall survival for first-line 
treatment with BRAF inhibitors, as the reported follow-
up periods for these agents (~3 years) are much shorter 
compared with that reported for ipilimumab (~7  years) 
[12, 13, 18, 26, 28, 34–38]. In the current study, among 
all four models used, the Weibull model provided a good 
fit of overall survival data for all four BRAF inhibitors. 
The Weibull model has also been previously used to build 
prognostic models for overall survival among patients 
with metastatic melanoma [39, 40].
Using the Weibull model as the base-case, the current 
study showed that ipilimumab was associated with the 
highest total life-months gained (28.5 months) relative to 
all BRAF inhibitors (ranging from 14.3 to 26.5  months) 
for the same 7-year follow-up period. Sensitivity analyses 
using the other three parametric survival models led to 
Table 1 Life-months gained
a Life-months were calculated by the area under the curve of the Kaplan–Meier curves of overall survival for different drugs
b Parametric survival modeling was used to extrapolate the survival probabilities of dabrafenib, trametinib, vemurafenib, and dabrafenib + trametinib. Weibull model 
was used as the primary model (results denoted with c). Other parametric models (exponential, Gompertz, and log-normal) were used as sensitivity analysis
Melanoma treatment Life‑months over all available follow‑up Projected life‑months for all drugs up to 7 yearsb
Life‑monthsa Weibull Exponential Gompertz Log‑normal
Ipilimumab 28.52 N/A N/A N/A N/A
Dabrafenib 21.47 26.51c 30.03 26.50 30.52
Trametinib 7.32 21.25c 26.53 16.94 36.69
Vemurafenib 13.00 14.28c 20.65 13.69 18.10
Dabrafenib + trametinib 16.78 24.55c 36.75 21.88 33.12
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Fig. 2 First-line ipilimumab overall survival for up to 7 years based on 
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a range of possible extrapolated total life-months gained 
for BRAF inhibitors. In these projections, BRAF inhibi-
tors sometimes, but never consistently, outperformed 
ipilimumab. Overall, combining base-case and sensitivity 
analysis results, this study showed no differences in terms 
of long-term survival between BRAF inhibitors com-
pared to ipilimumab for the first-line treatment of meta-
static melanoma.
Ipilimumab is administered in a fixed number of doses 
(4 doses over 3 months) and thus the drug costs are fixed, 
whereas BRAF inhibitors are dosed chronically and thus 
the drug costs are dependent upon the duration of treat-
ment. To provide a fair comparison of long-term costs, 
cumulative drug costs per life-month gained were com-
pared between ipilimumab and BRAF inhibitors. Such 
costs for BRAF inhibitors were constant and equal to 
the monthly cost of these treatments because by defi-
nition, total life-months gained included only patients 
alive and continuing treatment. The results showed that 
ipilimumab was associated with higher short-term cumu-
lative costs per life-month gained (e.g., years 1 and 2) 
compared with BRAF inhibitors, but the costs of ipili-
mumab per life-year gained continued to decline over 
time and by year 3 were below those of BRAF inhibi-
tors. With all available 7-year follow-up, ipilimumab 
was associated with cumulative costs per life-month 
gained of $4281, which was ~50 to 60 % less than those of 
BRAF monotherapies and ~80 % less than those of dab-
rafenib + trametinib combination therapy. These calcula-
tions are based on the assumption that patients treated 
with ipilimumab receive all four doses, when in practice 
approximately 78  % of patients receive the full, 4-dose 
regimen [43]. Thus, ipilimumab’s costs per life-month 
gained results are conservative.
The findings of this study have important implications 
for healthcare decision makers. Despite initial lower 
response rates, an immune-oncology agent with estab-
lished long-term efficacy like ipilimumab can provide a 
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lasting survival benefit for a subset of patients and result 
in lower costs overall. These are important considera-
tions for third-party payers in particular, who are faced 
with rapidly-increasing healthcare expenditures.
There are several limitations with the current study. 
First, sensitivity analyses of parametric survival mod-
eling of overall survival showed that estimated total life-
months gained by BRAF inhibitors were sensitive to the 
specific model used. Therefore, there were uncertain-
ties with current findings, so they should be interpreted 
with caution. Second, trametinib data included mixed 
first- and second-line treatments, as the METRIC trial 
[34] was the only RCT for trametinib. Thus, survival 
results for trametinib used in this study might be under-
estimated. Third, the current analysis used first-line ipili-
mumab data from a pooled analysis of 12 clinical studies 
[18], which included patients treated with the on-label 
dose of 3 mg/kg, as well as other experimental doses (0.1, 
0.3, 1, 2, 5, 9, and 10 mg/kg). However, we did not expect 
the use of various doses to significantly affect our find-
ings, as Schadendorf et  al. 2015 noted similar efficacy 
with all doses [18]. Fourth, in the calculation of drug 
costs per life-month gained, only the wholesale acquisi-
tion costs (WAC) of drugs were used. Other important 
cost components, such as drug administration costs, 
patient out-of-pocket costs, and costs for managing 
adverse events, were not considered. Fifth, BRAF muta-
tion status was not available in the patient-level data of 
ipilimumab. Thus, the results for ipilimumab were based 
on all patients with metastatic melanoma, irrespective 
of BRAF mutation status, whereas the results for BRAF 
inhibitors were based on patients with BRAF mutation 
only. Sixth, many of the included trials did not have con-
trol arms given the agents’ effectiveness in preclinical 
and early clinical testing. In addition, there was a high 
degree of heterogeneity among the studies with control 
arms in terms of chemotherapies administered. Thus, a 
chemotherapy control could not be incorporated into the 
current study, and the life-months gained for all drugs 
are relative to no treatment (and not relative to standard 
of care/chemotherapy). Adding a chemotherapy con-
trol would reduce the estimated life-months gained and 
likely lower the costs per life-months gained for all treat-
ments. Finally, at the time of study, newer programmed 
cell death protein-1 (PD-1)-targeting agents nivolumab 
and pembrolizumab had not been approved for first-
line use and thus they were not included in the current 
analyses. Currently, the National Comprehensive Can-
cer Network (NCCN) guidelines recommend nivolumab 
(category 1) and pembrolizumab as systemic, first-line 
therapies for metastatic or unresectable melanoma [7]. 
The UK National Institute for Health and Care Excel-
lence (NICE) has recommended nivolumab as an option 
for treating advanced melanoma, and pembrolizumab 
as a second-line option for treating advanced melanoma 
following disease progression with ipilimumab (or a first-
line option when a discount is provided) [44, 45]. In addi-
tion, nivolumab +  ipilimumab combination therapy has 
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recently been granted an accelerated approval as a treat-
ment for BRAF V600 wild-type unresectable or meta-
static melanoma in the US based on findings from the 
CheckMate-069 [24, 46]. Future studies on PD-1 agents 
are needed.
Conclusions
Ipilimumab was associated with a better long-term cost-
per-life month compared with BRAF inhibitors. Long-
term extrapolation of survival with BRAF inhibitors was 
uncertain and showed no evidence of prolonged survival 
compared with ipilimumab.
Methods
Data sources
For ipilimumab, patient-level data from 12 clinical stud-
ies (MDX010-20, CA184024, CA184022, CA184008, 
CA184007, CA184004, CA184042, CA184332, 
CA184338, NCI04C0083, and NCI03C0109) was used. 
These studies were described in detail in Schadendorf 
et al. 2015 [18]. The current analysis focused specifically 
on first-line use of ipilimumab. Drug costs were based 
on WAC from RED BOOK Online® (as of April 2015). 
Reported overall survival results for BRAF inhibitors 
were systematically reviewed and extracted from pub-
lished RCTs.
Systematic literature review
A systematic literature review of clinical trials of BRAF 
inhibitors was performed on August 18, 2014. The data-
bases included in this search were: MEDLINE (Incep-
tion—August 18, 2014), MEDLINE In-Process (up to 
August 18, 2014), EMBASE (Inception—August 18, 
2014), and the Cochrane Central Register of Controlled 
Trials (Inception—August 18, 2014). In addition, con-
ference proceedings from 2012–2014 ASCO and ESMO 
annual conferences were manually searched to supple-
ment the database search results. During the search 
process, two researchers reviewed all the citations inde-
pendently. Any disagreements were resolved by discus-
sion with, or independent arbitration by, a third reviewer. 
In order to be included for this study, eligible publications 
had to (1) have been conducted among adult patients 
with unresectable or metastatic (stage IIIc or IV) mela-
noma, (2) include phase II/III clinical trials of at least 50 
patients, (3) include first-line treatment of dabrafenib, 
trametinib, vemurafenib, or trametinib + dabrafenib, and 
(4) include one of the following efficacy outcomes: OS, 
progression-free survival (PFS) or time to progression 
(TTP), or response rates. For included studies, relevant 
data were extracted into a data collection spreadsheet 
with prepared fields.
Statistical analyses
Total life-months gained were calculated as the area 
under the curve of the Kaplan–Meier curve of overall 
survival (the sum of time multiplied by the proportion of 
patients who are alive at that time) for each agent. First, 
total life-months gained for all drugs were calculated 
based on the observed overall survival for available fol-
low-up periods. Then, total life-months gained for BRAF 
inhibitors were calculated based on the extrapolated 
overall survival from parametric survival modeling. The 
cumulative costs per life-month gained were calculated 
by dividing the cumulative total drug costs by the total 
life-months gained for each drug. Cumulative total drug 
costs were calculated based on WAC and on-label dosing.
Kaplan–Meier analysis was conducted using patient-
level data of first-line ipilimumab. For BRAF inhibi-
tors, data from published overall survival Kaplan–Meier 
curves of included studies were extracted using Engauge 
digitization software to create “pseudo” patient-level data 
using methodology recommended by NICE [47]. Differ-
ent parametric survival models, including exponential, 
Gompertz, log-normal, and Weibull models, were used 
to fit the “pseudo” patient-level data and subsequently 
project long-term OS. The AIC values of different mod-
els were compared to help select the model for base-case 
and sensitivity analyses. The area under the curve of the 
observed and projected overall survival Kaplan–Meier 
curves were calculated to derive the total life-months 
gained. Both total life-months gained and cumulative 
costs per life-month gained were compared descriptively 
between ipilimumab and BRAF inhibitors. All analyses 
were conducted in R statistical software.
Abbreviations
AIC: Akaike information criterion; ASCO: American Society of Clinical Oncol-
ogy; AUC: area under the curve; ESMO: European Society for Medical Oncol-
ogy; MEK: mitogen activated protein kinase/extracellular signal-regulated 
kinase; NICE: National Institute for Health and Care Excellence; OS: overall 
survival; PFS: progression-free survival; TTP: time to progression; RR: response 
rate; WAC: wholesale acquisition cost.
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